A Multicenter, Open-Label, Functionality, Reliability and Performance Study of a Single-Use Auto-Injector With Home-administered Subcutaneous Benralizumab in Adult Patients With Severe Asthma (GRECO)
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Benralizumab (Primary)
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Acronyms GRECO
- Sponsors AstraZeneca
- 04 Oct 2019 According to an AstraZeneca media release, the US Food and Drug Administration (FDA) has approved the self administration of FASENRA (benralizumab) in a pre-filled, single use auto-injector.This approval is supported by data from Phase III GRECO and Phase I AMES trials.
- 25 Feb 2019 Results of autoinjector functionality and reliability data presented at the 2019 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
- 19 Sep 2017 Status changed from active, no longer recruiting to completed.